— Know what they know.
Not Investment Advice

TLSI NASDAQ

TriSalus Life Sciences, Inc.
1W: +3.8% 1M: -13.4% 3M: -13.2% YTD: -37.7% 1Y: -25.8% 3Y: -21.6% 5Y: -61.7%
$3.80
+0.18 (+4.97%)
After Hours: $3.74 (-0.06, -1.71%)
Weekly Expected Move ±6.1%
$3 $3 $4 $4 $4
NASDAQ · Healthcare · Medical - Devices · Tech Score Strong Sell · Power 36 · $234.0M mcap · 38M float · 0.796% daily turnover · Short 52% of daily vol
Credit Risk of going bust: higher than 75% of companies Debt: 13.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.09 (down 98%), TriSalus Life Sciences, Inc. would be worth roughly what it owes.
Total debt $34.4M against a stock market value of $222.9M.
Distance to default 3.00 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $16.5M (short-term plus half of long-term), stock volatility 85.4%; Altman Z -4.72. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

📊 Key Metrics

TTM
$45M
Revenue
+25.2% YoY
$-28M
Net Income
+9.5% YoY
$-30M
Free Cash Flow
-2.2% YoY
86.8%
Gross Margin
-86.0%
Op. Margin
-80.5%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

⚠️ Cash Burn Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE438.3%
ROA-54.4%
ROIC453.7%

Valuation

P/E-2.9
P/B34.0
EV/EBITDA-11.7

Leverage

Debt/Equity5.26
Current Ratio5.35
Interest Cov.-3.8x

Quality Scores

Piotroski F4/9
Altman Z-4.26
Beneish M-2.57

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms